HIV and viral hepatitis coinfections: advances and challenges

摘要: With a prevalence affecting over 30% of HIV infected patients, coinfection with hepatitis B (HBV) or C (HCV) virus remains one the most frequent comorbidities in this population, significant impact terms morbidity and mortality associated liver disease. Recent findings physiopathology have confirmed that it may contribute, along hepatotoxicity antiretrovirals burden metabolic diseases, to more rapid progression fibrosis, especially when there is underlying chronic coinfection. Both fields research clinical appraisal HBV HCV are rapidly evolving prompt change former paradigms care management hepatic context HIV. The advent anti-HCV direct antiviral agents has indeed completely shaken up treatment guidelines for HCV, tricky these new means referring patients specialised centres. In coinfection, therapeutic options not changed recently but challenges emerged regarding low replicating HBV-DNA optimally treated long term exposure antivirals. Finally, global increase life expectancy been accompanied coinfected by higher risk emergence end stage diseases which access orthotopic transplantation innovative procedures such as targeted hepatocellular carcinoma therapies should be facilitated.